Immunotherapy targeting immune checkpoints (e.g. PD-1/L1, CTLA-4, etc.) has revolutionized our management of various tumors, including lung cancer. However only a minority of lung cancer patients benefit directly from immunotherapy, and many of them may develop immune-related adverse effects (irAEs) that could further limit the therapeutic value of immunotherapy. Finding the right patient population, uncoupling the therapeutic response from irAEs, and broadening the application under various clinical settings are therefore urgently important - indeed, they represent therapeutic challenges and opportunities in lung cancer immunotherapy.
The goal of this collection is to address above-mentioned challenges and opportunities via the following research areas:
1) identify better predictive biomarkers;
2) enhance therapeutic response from immunotherapy;
3) early recognition and management of irAEs;
4) innovative approaches to uncouple therapeutic response and irAEs;
5) novel immune checkpoints and immunotherapeutic interventions, as well as novel therapeutic combinations;
6) use of immunotherapy under various clinical conditions.
We welcome both preclinical and clinical original research articles and reviews addressing the following (but not limited to the following) research topics:
- Early recognition and clinical management of irAEs. The mechanistic dissection of irAEs and the potential approach to uncouple irAEs from immunotherapy response
- The use of microbiome, extracellular vesicles, genomic/proteomic signatures to predict response and irAEs
- Enhancing immunotherapy response via targeting the tumor immune microenvironment, metabolic reprogramming of cancer and/or immune cells, cytokine signaling, combination of innate and adaptive immunity, using novel immune checkpoints, novel delivery of immune cells and/or therapeutic agents, as well as novel therapeutic approaches
- The use of immunotherapy in the neoadjuvant and adjuvant settings
COIs:
Dr. Jarushka Naidoo has had research funded by Merck, AstraZeneca, and Bristol Myers Squibb
Dr. Oscar Arrieta has had research funded by National Council for Science and Technology in Mexico (CONACyT), Pfizer, AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Bristol-Myers Squibb, and Roche
Dr. Zhang has served as a scientific advisor/consultant for: AstraZeneca, Biodesix, Novocure, Bayer, Daiichi Sankyo, Mirati, Novartis, Cardinal Health, Bristol-Myers Squibb, Nexus Health and Sanofi. He is on the speakers’ bureau for AstraZeneca, Regeneron, Sanofi and MJH Life Sciences. Dr. Zhang has also received previous research funding from AstraZeneca, Biodesix, Novartis, Genentech/Roche, Mirati, AbbVie and Hengrui Therapeutics
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Immunotherapy targeting immune checkpoints (e.g. PD-1/L1, CTLA-4, etc.) has revolutionized our management of various tumors, including lung cancer. However only a minority of lung cancer patients benefit directly from immunotherapy, and many of them may develop immune-related adverse effects (irAEs) that could further limit the therapeutic value of immunotherapy. Finding the right patient population, uncoupling the therapeutic response from irAEs, and broadening the application under various clinical settings are therefore urgently important - indeed, they represent therapeutic challenges and opportunities in lung cancer immunotherapy.
The goal of this collection is to address above-mentioned challenges and opportunities via the following research areas:
1) identify better predictive biomarkers;
2) enhance therapeutic response from immunotherapy;
3) early recognition and management of irAEs;
4) innovative approaches to uncouple therapeutic response and irAEs;
5) novel immune checkpoints and immunotherapeutic interventions, as well as novel therapeutic combinations;
6) use of immunotherapy under various clinical conditions.
We welcome both preclinical and clinical original research articles and reviews addressing the following (but not limited to the following) research topics:
- Early recognition and clinical management of irAEs. The mechanistic dissection of irAEs and the potential approach to uncouple irAEs from immunotherapy response
- The use of microbiome, extracellular vesicles, genomic/proteomic signatures to predict response and irAEs
- Enhancing immunotherapy response via targeting the tumor immune microenvironment, metabolic reprogramming of cancer and/or immune cells, cytokine signaling, combination of innate and adaptive immunity, using novel immune checkpoints, novel delivery of immune cells and/or therapeutic agents, as well as novel therapeutic approaches
- The use of immunotherapy in the neoadjuvant and adjuvant settings
COIs:
Dr. Jarushka Naidoo has had research funded by Merck, AstraZeneca, and Bristol Myers Squibb
Dr. Oscar Arrieta has had research funded by National Council for Science and Technology in Mexico (CONACyT), Pfizer, AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Bristol-Myers Squibb, and Roche
Dr. Zhang has served as a scientific advisor/consultant for: AstraZeneca, Biodesix, Novocure, Bayer, Daiichi Sankyo, Mirati, Novartis, Cardinal Health, Bristol-Myers Squibb, Nexus Health and Sanofi. He is on the speakers’ bureau for AstraZeneca, Regeneron, Sanofi and MJH Life Sciences. Dr. Zhang has also received previous research funding from AstraZeneca, Biodesix, Novartis, Genentech/Roche, Mirati, AbbVie and Hengrui Therapeutics
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
